 Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Incs NASDAQ: VYGR investigational new drug application for VY-HTT01, a gene therapy candidate for Huntingtons disease HD. The agency has confirmed that the company may proceed with its planned Phase 12 clinical trial. 